{"disease":{"id":"chemotherapy-induced-neutropenia","name":"Chemotherapy-induced neutropenia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"nivestym","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"nyvepria","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neulasta","generic_name":"Pegfilgrastim-Apgf","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor on hematopoietic cells","drug_class":"Colony-stimulating factor","quality_score":10,"revenue":"1200","mechanism":"Colony-stimulating factor binding hematopoietic cell surface receptors to stimulate proliferation and differentiation."},{"drug_id":"lipegfilgrastim","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lonquex","generic_name":"LIPEGFILGRASTIM","company_name":"Sicor Biotech UAB","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":28,"revenue":"1200","mechanism":""},{"drug_id":"pegfilgrastim-jmdb","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"FULPHILA","generic_name":"PEGFILGRASTIM-JMDB","company_name":"MYLAN GMBH","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pegfilgrastim","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neulasta","generic_name":"PEGFILGRASTIM","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":70,"revenue":null,"mechanism":"Neulasta stimulates the production of white blood cells by binding to their receptors."},{"drug_id":"neupogen","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"neulasta","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neulasta","company_name":"Columbia University","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"sargramostim","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leukine","generic_name":"SARGRAMOSTIM","company_name":"Berlex Labs","drug_phase":"marketed","molecular_target":"Granulocyte macrophage colony-stimulating factor receptor","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":10,"revenue":null,"mechanism":"Leukine works by binding to the granulocyte macrophage colony-stimulating factor receptor, stimulating the production of white blood cells."},{"drug_id":"leukine","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Leukine","company_name":"University of Kentucky","drug_phase":"discontinued","molecular_target":"Granulocyte macrophage colony-stimulating factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03846414","title":"Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02178475","title":"Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":943,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04460079","title":"Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN","phase":"","overall_status":"COMPLETED","enrollment_count":654,"lead_sponsor_name":"Cinnagen","has_results":false},{"nct_id":"NCT01126190","title":"Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":381,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT06616571","title":"Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":336,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT00837265","title":"Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":334,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT07096479","title":"Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor","phase":"","overall_status":"RECRUITING","enrollment_count":318,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT05245487","title":"Danish Elder Lymphoma Patient Hematopoietic Investigation","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06809101","title":"Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.","phase":"","overall_status":"RECRUITING","enrollment_count":265,"lead_sponsor_name":"Pomeranian Medical University Szczecin","has_results":false},{"nct_id":"NCT07192770","title":"G-CSF-Induced Bone Pain and Supportive Care Approaches","phase":"","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT03294577","title":"Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":221,"lead_sponsor_name":"BeyondSpring Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT02465801","title":"Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Tianjin SinoBiotech Ltd.","has_results":false},{"nct_id":"NCT04101760","title":"Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT06649448","title":"A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT04460508","title":"Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":170,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT06926751","title":"Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":132,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06537726","title":"Breath Analysis for the Detection of Invasive Fungal Infections","phase":"","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT04000711","title":"Safety and Efficacy of Ambulatory Versus In-hospital Antibiotic Treatment in Children With Febrile Neutropenia","phase":"NA","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Hospital Infantil de Mexico Federico Gomez","has_results":false},{"nct_id":"NCT04227990","title":"Plinabulin iv Solution in Prevention of TAC Induced Neutropenia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"BeyondSpring Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03102606","title":"Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"BeyondSpring Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT03793205","title":"G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04448314","title":"Study to Evaluate the Usability of PointCheck","phase":"","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Leuko Labs, Inc.","has_results":false},{"nct_id":"NCT04887831","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":92,"lead_sponsor_name":"G1 Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03251768","title":"Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Tianjin SinoBiotech Ltd.","has_results":false},{"nct_id":"NCT04345900","title":"Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"BeyondSpring Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT05512676","title":"Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT03208816","title":"Community-Led Action Research in Oncology: Improving Symptom Management","phase":"NA","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false},{"nct_id":"NCT03246009","title":"Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Tianjin SinoBiotech Ltd.","has_results":false},{"nct_id":"NCT04134429","title":"Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":true},{"nct_id":"NCT04914702","title":"Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT03559387","title":"Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Prolong Pharmaceuticals","has_results":false}],"total":31},"guidelines":[{"drug_id":"nivestym","guideline_body":"FDA label","recommendation":"Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.","line_of_therapy":"adjuvant","evidence_grade":"not specified","guideline_year":null},{"drug_id":"nyvepria","guideline_body":"FDA label","recommendation":"NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}